IDEXX Laboratories, Inc.


SKU: IDXX Category:


IDEXX Laboratories: Growing Global Direct Commercial Capability


In 2023, IDEXX Laboratories posted strong quarterly and annual results. The company reported an 8% organic revenue increase in Q4, largely driven by gains in CAG Diagnostic recurring revenues. Operating profits also rose 8% as reported, with a 10% increase on a comparable basis, aided by robust gross margin gains and OpEx leverage. The lower-than-anticipated effective tax rate enabled the company to deliver an EPS of $2.32 in Q4, reflecting an increase of 17% on a comparable basis. For the full year, the company reported a 9% rise in overall organic revenue and significant comparable operating margin gains, leading to a 29% rise in EPS.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!